Smriti Mandhana helped India gain a 1-0 lead in the five-match T20I series against England as he hit her first century in the shortest format of the game. Her 112-run knock helped India post 210/5 in the allotted twenty overs. The hosts were then bundled out for 113 as Nallapureddy Charani returned with four wickets while Deepti Sharma and Radha Yadav scalped two each.
Here are all the live streaming details for the 2nd T20I between India Women and England Women. (AP)
Smriti also led from the front as she was the captain in the first T20I in the absence of Harmanpreet Kaur. She missed the series opener following an injury that she sustained during a warm-up match against the ECB Select XI.
Harleen Deol got a chance in Harmanpreet Kaur’s place. However, the management now have a lot to ponder upon as the right-handed batter performed well, scoring 43 runs off 23 balls with the help of seven fours.
If Harmanpreet Kaur is deemed fit for the contest, then it needs to be seen who she replaces in the playing XI. Regarding England, nothing went right for the hosts. Skipper Nat Sciver-Brunt was the only bright spot, scoring 66 runs off 42 balls with the help of 10 fours.
England Women: Nat Sciver-Brunt (C), Em Arlott, Tammy Beaumont (wk), Lauren Bell, Alice Capsey, Charlie Dean, Sophia Dunkley, Sophie Ecclestone, Lauren Filer, Amy Jones (wk), Paige Scholfield, Linsey Smith, Danni Wyatt-Hodge, Issy Wong.
Here are all the live streaming details for the 2nd T20I between India and England Women
When will the India Women vs England Women 2nd T20I match be played?
The India Women vs England Women 2nd T20I match will be played on Tuesday, July 1. The match will begin at 11 PM IST with the toss scheduled for 10:30 PM IST.
Where will the India Women vs England Women 2nd T20I match be played?
The India Women vs England Women 2nd T20I match will be played at the Bristol County Ground.
Which channels will broadcast the India Women vs England Women 2nd T20I match?
The India Women vs England Women 2nd T20I match will be telecast live on the Sony Sports network.
Where will live streaming be available for the India Women vs England Women 2nd T20I match?
The India Women vs England Women 2nd T20I match will be streamed live on the SonyLiv and Fancode app and website.
The investigation will be carried out by the department of anesthesiology at Suzhou Ninth People’s Hospital, an affiliated hospital of Soochow University. Our hospital’s anesthesiology department is recognized as a key clinical discipline in the region. With around 5000 laparoscopic surgery patients treated annually, the hospital will provide a sufficient patient population to ensure an adequate sample size for the study. Figure 1 illustrates the research workflow.
Fig. 1
Study flow diagram. PONV, postoperative nausea and vomiting
Eligibility criteria {10}
Inclusion criteria
1.
Participants aged 18 to 65 years old.
2.
American Society of Anesthesiologists (ASA) physical status I to III.
3.
Body mass index (BMI) between 18 and 30 kg/m2.
4.
Scheduled to perform general anesthesia with endotracheal intubation for laparoscopic surgery, including appendectomy, laparoscopic cholecystectomy and laparoscopic hernia repair.
5.
Expected duration of surgery between 30 and 120 min.
Exclusion criteria
1.
Sick sinus syndrome or severe bradycardia (heart rate less than 50 beats per minute).
2.
History of hypertension or cardiac insufficiency.
3.
Second-degree or higher atrial block without a pacemaker.
4.
Left ventricular ejection fraction less than 40%.
5.
Diagnosed with coronary artery disease or history of myocardial infarction.
6.
Hepatic or renal insufficiency, Child–Pugh class C, or undergoing renal replacement therapy.
7.
Parkinson’s disease or Alzheimer’s disease.
8.
Seizures or epilepsy.
9.
Current pregnancy or lactation status.
10.
History of persistent pain or prior use of sedatives or analgesics.
11.
Known allergies to the drugs used in this study.
12.
Participation in another clinical trial within the past 30 days.
13.
History of substance abuse.
14.
Psychiatric illness or current use of antipsychotic medications.
15.
Communication disorders such as deafness or cognitive impairment.
16.
Anticipated difficult airway or history of difficult intubation.
Drop out criteria
Participants will not be excluded from the final analysis solely due to adverse events or other post-randomization occurrences. All randomized participants will be included in the intention-to-treat (ITT) analysis.
However, the following circumstances will be considered as dropouts, and the reasons will be recorded in detail:
1.
Withdrawal of informed consent for continued participation or data use.
2.
Loss to follow-up before the assessment of primary or secondary outcomes.
3.
Conversion from laparoscopic to open surgery.
4.
Use of non-permitted medications, including:
– Additional antiemetics not specified in the protocol.
– Perioperative corticosteroids.
– Sedatives or analgesics outside the study regimen.
5.
Non-collection of data.
In contrast, the following events will be considered protocol deviations and addressed in sensitivity analyses:
1.
Non-administration of the study drug.
2.
Unplanned additional surgical procedures.
3.
Minor violations of timing or dosage not affecting outcome measurement.
Screening failures (participants who do not meet eligibility criteria before randomization) will be recorded separately and excluded from all analyses. All dropout events and reasons will be meticulously documented in the case report forms (CRFs) and stored for auditing and future reference.
Consent or assent {26a, 26b}
Eligible patients will be approached by research team members, all of whom are licensed medical doctors, to be invited to participate in the study. Detailed instructions regarding the study protocol, procedures, and potential risks and benefits will be provided in clear language. Written informed consent will be obtained from each participant one day prior to surgery to ensure voluntary participation and adequate understanding of the research process.
Explanation for the choice of comparators {6b}
To provide a rigorous comparison, the comparator in this trial is the standard anesthetic regimen routinely used at our institution, consisting of intravenous induction with sufentanil and propofol, followed by maintenance with sevoflurane and a continuous remifentanil infusion. This approach is widely adopted in clinical practice and provides effective intraoperative analgesia with minimal postoperative sedation, making it particularly suitable for laparoscopic surgeries [11, 29]. The intervention group protocol is informed by the principles of OFA, where dexmedetomidine and esketamine are commonly utilized to achieve adequate analgesia and sedation while minimizing opioid exposure. The selected drug combination and administration strategy are based on published OFA studies and adapted for routine clinical application [13, 21, 25]. Given the established link between intraoperative opioid use and PONV, this study aims to determine whether an opioid-reducing approach incorporating these agents can improve PONV outcomes and postoperative recovery compared to the standard opioid-based regimen.
Interventions {11a, 11b, 11c, 11d}
Patients will be randomized into two groups using a computer-generated random number table at a 1:1 ratio, comprising the combination therapy group (dexmedetomidine and esketamine) and the control group. In the combination therapy group, anesthesia induction will involve intravenous infusion of dexmedetomidine (0.5 μg/kg over more than 10 min), followed by intravenous bolus administration of esketamine (0.3 mg/kg), sufentanil (0.2 μg/kg), and propofol (1.5–2.0 mg/kg). Anesthesia will be maintained with 2–3% sevoflurane. In the control group, anesthesia induction will consist of intravenous bolus administration of sufentanil (0.5 μg/kg) and propofol (1.5–2.0 mg/kg), while maintenance will include 2–3% sevoflurane inhalation and continuous intravenous infusion of remifentanil at 0.1 μg/kg/min. The selected remifentanil dose is within the low range and below thresholds typically associated with remifentanil-induced hyperalgesia, as supported by previous studies [30, 31].
All patients will receive 5 mg of dexamethasone intravenously after anesthesia induction, 4 mg of tropisetron at the end of surgery, and 50 mg of flurbiprofen axetil approximately 30 min before surgery completion to prevent PONV and manage postoperative pain. The intraoperative monitoring protocol includes ECG, SpO2, non-invasive blood pressure, and end-tidal CO₂, with anesthesia depth maintained within a BIS range of 40–60. Vital signs will be continuously monitored using standard multi-parameter monitors. The dosages of anesthetic agents in both groups are derived from published literature and institutional protocols, with remifentanil and sufentanil dosing in the control group based on perioperative anesthesia studies [13, 32], and dexmedetomidine and esketamine dosing in the combination group adapted from opioid-free anesthesia protocols [13, 21].
Postoperative management will also be standardized. Pain and PONV assessments will be conducted at fixed time intervals: 0–6 h (PACU), 6–24 h, and 24–48 h after surgery. Pain intensity will be evaluated using the numerical rating scale (NRS) at 0, 6, 12, 24, and 48 h. Time to first PONV episode, time to first rescue medication use, and total dosage/frequency of rescue analgesics and antiemetics within 48 h will be recorded. Postoperative adverse events such as nightmares, drowsiness, bradycardia, length of hospital stay, and discharge condition will also be documented.
Rescue interventions are standardized. For pain (NRS ≥ 4), 5 mg of dezocine will be administered intravenously. Severe PONV, defined as ≥ 3 vomiting episodes or inability to perform daily activities, will be managed with 10 mg of azasetron; persistent vomiting post-treatment may lead to study withdrawal. Adverse reactions such as esketamine-related nightmares will be treated with 2 mg midazolam, while drowsiness will be managed with observation or opioid antagonists like naloxone in severe cases. Bradycardia (HR < 55 bpm) will be treated with 0.25 mg atropine or 2 μg isoproterenol and anesthetic dose adjustment.
To enhance adherence and consistency, interventions will be performed under general anesthesia, eliminating the need for patient cooperation during drug administration. Postoperative assessments will be carried out by trained personnel at predefined time points using standardized tools. Rescue medication criteria are clearly defined to minimize variability. Preoperative briefings for nursing and anesthesiology teams will ensure uniform postoperative care. The overall trial process, including patient enrollment, treatment, and data collection, will follow the SPIRIT guidelines as detailed in Table 2.
Table 2 Schedule of patient enrolment, study interventions and outcome assessment
Outcomes {12}
Primary outcome
Postoperative pain and nausea severity will be assessed using the Numerical Rating Scale (NRS), an 11-point scale ranging from 0 (no symptom) to 10 (worst imaginable pain or nausea), based on patient self-report at predefined postoperative intervals. The incidence of nausea will be defined as any self-reported score ≥ 1, while vomiting will be defined as any observed or self-reported episode of forceful expulsion of gastric contents. Both nausea and vomiting episodes will be recorded separately by trained clinical staff through direct observation and/or patient reports. The primary outcome of this study is the incidence of PONV (including both nausea and vomiting) within 48 h after surgery. PONV will be assessed by trained clinical staff during three defined time intervals: 0–6 h, 6–24 h, and 24–48 h postoperatively. Both nausea and vomiting episodes will be recorded separately to allow for detailed analysis.
Secondary outcomes
Preoperatively, the Apfel simplified risk score will be used to evaluate each patient’s baseline risk of PONV, assigning one point for each of the following: female sex, non-smoking status, history of motion sickness or previous PONV, and anticipated postoperative opioid use (total score range: 0–4). The secondary outcomes include:
1.
Preoperative Apfel PONV risk score.
2.
NRS pain scores of the patients recorded at 0 h (in the PACU), 6 h, 12 h, 24 h, and 48 h after surgery.
3.
Time to first PONV episode and time to first rescue antiemetic administration.
4.
Time to first rescue analgesic administration.
5.
Total dosage and frequency of rescue analgesics and antiemetics within 48 h.
6.
Patient satisfaction score at discharge, rated on a 5-point Likert scale.
7.
Length of hospital stay (in days).
8.
Discharge condition score, assessed by the attending physician.
9.
Incidence and classification of AEs.
Participant timeline {13}
The timeline for participant involvement is illustrated in Table 2.
Sample size calculation {14}
In a recent investigation, OFA demonstrated a 65% reduction in the likelihood of PONV following laparoscopic gynecological surgery, decreasing the incidence from 42.5 to 15.0% (10). For the power analysis, we assume a baseline PONV incidence of 40% in laparoscopic surgery under traditional opioid anesthesia. With the hypothesis of a 50% average reduction in PONV, our combination therapy strategy is anticipated to lower the PONV incidence to 25%. To achieve a statistical power of 80% with a bilateral α level of 0.05, 64 patients per group will be deemed necessary to detect intergroup differences in PONV. Considering potential withdrawals, a planned recruitment of 140 patients will be intended, with 70 in each group. The sample size is determined using PASS software (V.11.0.7, NCSS, Kaysville, UT, USA).
Recruitment {15}
Patients participating in this study were enlisted from the anesthesia department. Our recruitment information was disseminated through the WeChat public platform. Additionally, soliciting recommendations from medical personnel constituted a significant aspect of our recruitment efforts. Furthermore, recruitment posters were prominently displayed in areas like the hospital outpatient and inpatient departments.
Allocation {16a, 16b, 16c}
In this study, randomization tables will be generated using IBM SPSS Statistics version 26.0 and maintained by independent statisticians overseeing the trial. Eligible participants will be randomly allocated to either the combination therapy group or the control group in a 1:1 ratio. To ensure allocation concealment, the randomization assignments will be enclosed in sealed, opaque envelopes and securely stored in a designated office. Neither the participants nor the investigators involved in clinical care or outcome assessment will be informed of group assignments, thereby maintaining the double-blind design. In cases of emergency or where clarification is required, only designated researchers will have access to the allocation list. Before surgery, coded study medications will be distributed to study personnel. The allocation sequence will remain confidential, accessible only to the principal investigator (PI) and an independent, unblinded researcher responsible for study drug preparation. The PI will assign participants to treatment groups according to the randomization list, while the unblinded researcher, who will not be involved in drug administration, anesthesia management, or outcome assessment, will prepare the corresponding study medications.
Blinding {17a, 17b}
To maintain double-blinding, each study syringe will be labeled solely with the participant’s unique identification number, without revealing the group allocation. The unblinded researcher, who is not involved in clinical care or outcome assessment, will prepare the study medication according to the randomization list and ensure that all other clinical staff and participants remain blinded throughout the trial. To ensure identical appearance and preserve blinding, both dexmedetomidine and esketamine (or their corresponding placebo components) will be diluted with 0.9% normal saline to a total volume of 20 ml. The final preparations, which are colorless and transparent, will be loaded into identical 20 ml syringes and handed over to the anesthesiologist immediately prior to anesthesia induction. All study personnel involved in clinical care, anesthesia management, outcome assessment, and data collection, as well as the participants themselves, will remain blinded to treatment allocation until data collection is completed and final analyses are conducted. In the event that unblinding is necessary due to medical emergencies or other justified reasons, access to allocation information will be strictly limited to designated personnel responsible for medication distribution.
Data collection methods {18a, 18b}
The subsequent data will be gathered as follows:
Preoperatively
1.
Patient’s general information (including height, weight, ASA classification, level of education, smoking habits, history of motion sickness, previous opioid use, allergies and surgical history).
2.
Apfel PONV risk score.
3.
Baseline NRS pain score.
4.
Results of laboratory tests.
Intraoperatively
1.
Hemodynamic parameters (such as NBP, HR, ECG and SpO2).
2.
Surgical details (including duration of operation, anesthesia, pneumoperitoneum, dosage and concentration of anesthetic agents administered, blood loss, volume of fluid replacement, urine output, and body temperature).
Post-surgery
1.
Incidence of nausea and vomiting will be assessed at three intervals: 0–6 h (in the PACU), 6–24 h, and 24–48 h after surgery.
2.
NRS pain scores will be recorded at 0 h (PACU), 6 h, 12 h, 24 h, and 48 h postoperatively.
3.
Time to first PONV episode, time to first rescue antiemetic or analgesic administration, and the total dosage and frequency of rescue medications.
4.
Incidence of AEs.
5.
Postoperative laboratory results.
6.
Length of hospital stay and discharge condition.
All patient data will be meticulously recorded in a case report form by a designated independent researcher. These records will then be entered into an electronic database under the careful supervision of the PI. Oversight of data collection will be managed by a Data Monitoring Committee (DMC), with final analysis conducted by impartial statisticians.
To promote participant retention and ensure complete follow-up, investigators will provide a comprehensive explanation of the study protocol and expected outcomes during the preoperative assessment. Efforts will be made to maximize participants’ understanding of the study procedures through detailed instruction and clear guidance, thereby enhancing their compliance and engagement throughout the study period.
Data management {19}
Prior to commencing the study, members of our trial team will undergo training in the collection, management, storage and confidentiality of data to ensure comprehension and compliance with pertinent policies and regulations. Patient data will be securely stored in both paper and electronic formats. Coded paper records will be kept in designated, locked storage areas. Data entry for the study will be conducted using a password-protected Microsoft Access database by two trained team researchers employing a double-entry method, and the accuracy of entries will be verified against the electronic database. To minimize the risk of data loss, researchers will perform incremental backups on a daily basis.
Statistical analysis {20a, 20b, 20c}
The Shapiro–Wilk test will be employed to assess the normality of data distribution. Data will be presented as mean (standard deviation), median (interquartile range), or number (percentage), as appropriate. Descriptive statistics will be used primarily to summarize patient characteristics and baseline variables. Comparative analyses of perioperative variables and outcome measures will be performed using the Mann–Whitney rank sum test, chi-square test, or Fisher’s exact test, depending on data type and distribution. To evaluate the effect of combination therapy versus control, the median difference (MD) or odds ratio (OR) with corresponding 95% confidence intervals (CI) will be calculated.
Subgroup analyses of the primary outcome (PONV incidence) will be conducted based on gender, smoking status, and Apfel PONV risk score. No adjustments will be made for multiple testing in secondary outcome analyses, which will therefore be interpreted as exploratory. All statistical analyses will be conducted using IBM SPSS software (version 19.0; IBM SPSS, Chicago, IL, USA), with two-sided P-values < 0.05 considered statistically significant.
As the administration of study medications will be supervised by anesthesiologists, protocol adherence is expected to be high. Since outcome assessment is scheduled within 48 h postoperatively, the occurrence of missing primary outcome data is anticipated to be minimal. Any missing data will not be imputed.
Data monitoring {21a, 21b}
The data monitoring process for this study will be overseen by the monitoring manager, who is a member of the clinical trial management team at Suzhou Ninth Hospital Affiliated to Soochow University. This individual will be responsible for ensuring the proper preservation of informed consent documents, monitoring participant compliance, and verifying the validity and safety of the study data throughout the trial. Given the short duration of the study, the relatively small sample size, and the anticipated low incidence of serious adverse events (SAEs), no interim analysis is planned.
Harms {22}
All adverse events (AEs) will be closely monitored and documented throughout the perioperative period and until the patient is discharged from the hospital. Based on previous studies [27, 28], these include the following:
Neurological and psychiatric events: emergence delirium or agitation, dizziness, headache, visual or auditory hallucinations, excessive sedation (BIS < 40 or unresponsiveness), seizures.
4.
Injection site reactions or hypersensitivity: rash, pruritus, swelling, or anaphylaxis.
Each AE will be classified by severity into mild, moderate, or severe according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Severe adverse events (SAEs) are defined as unanticipated medical incidents that prolong hospitalization, result in persistent disability or dysfunction, pose a life-threatening risk, or cause death. If any SAE occurs, the infusion of dexmedetomidine and esketamine will be immediately discontinued, and the participant will be withdrawn from the study if necessary. All SAEs will be reported promptly to the Ethics Committee, and participants will be followed until the event resolves or stabilizes, or until hospital discharge, whichever comes later.
The attending anesthesiologists and trained research staff will be responsible for managing and recording all AEs and SAEs in the case report forms. An independent Data Monitoring Committee (DMC), composed of clinical experts not involved in the study, will review and categorize all AEs and SAEs according to predefined criteria. If a participant experiences more than three episodes of vomiting despite rescue treatment, or develops any SAE, the case will be considered for withdrawal from the study in accordance with the predefined discontinuation criteria.
Auditing {23}
There will be no plans for conducting formal trial audits.
Research ethics approval {24}
Ethical clearance for this investigation was granted by our hospital’s ethics committee on May 1, 2023 (2,023,067). Subsequently, the research protocol was registered with the China Clinical Trial Registry on June 14, 2023 (ChiCTR2300072455).
Protocol amendments {25}
Should there arise a need for protocol modifications, they will be duly registered at https://www.chictr.org.cn.
Confidentiality {27}
Confidentiality will be maintained for all potential and enrolled patients, with access restricted solely to the principal investigator. Anonymized patients will be assigned unique numerical identifiers (ID numbers) rather than names. Throughout the duration of the experiment, the DMC diligently oversees the database to enhance data integrity. Upon completion of the experiment, researchers will procure the results of statistical data analysis.
The story of Earth’s origins lies hidden in ancient stones, forged in a time of intense formation and volcanic activity. Recently, a groundbreaking discovery in northern Quebec has shed new light on the planet’s earliest days. Scientists have confirmed the presence of the oldest known rocks on Earth in a region near the village of Inukjuak, Nunavik. This remarkable find provides a rare glimpse into the Hadean eon, a mysterious and largely unknown chapter in Earth‘s history. The discovery has sparked intense scientific interest, offering new insights into the planet’s formation and evolution. It brings us closer to understanding the Earth’s unstable beginnings.
Oldest rocks found in Northern Quebec
According to earth.com, a groundbreaking study published in the journal Science has revealed the discovery of the oldest known rocks on Earth in northern Quebec, offering a rare glimpse into the planet’s earliest history. Collected in 2017 near the village of Inukjuak, Nunavik, these ancient rocks have sparked intense scientific interest due to their unusual properties and old composition. The research team employed advanced methods to determine the rocks’ age, settling a long-standing debate that had dated the rocks to anywhere between 3.75 and 4.3 billion years old. The team’s breakthrough came when they confirmed that intrusive rocks cutting through the volcanic layers were 4.16 billion years old, implying that the volcanic rocks themselves are even older.This remarkable find offers a rare glimpse into the Hadean eon, a period of Earth’s history marked by intense volcanic activity and a hostile environment.
How scientists accurately dated 4.16 billion-year-old rocks
To determine the age of the rocks, scientists employed radiometric dating, a precise technique that measures time based on the natural decay of elements within the rocks. They focused on samarium and neodymium, elements that undergo a slow and predictable transformation, with samarium decaying into neodymium at a known rate. By analysing the current ratio of these elements, scientists can calculate when the rock originally formed. The team used two independent isotope systems, both of which yielded the same result: the rocks solidified approximately 4.16 billion years ago. This method provides an accurate and reliable way to date ancient rocks, allowing scientists to reconstruct the Earth’s history.
Hadean Eon made Earth a planet, but it wasn’t ready for life yet
The Hadean eon marked the violent and chaotic birth of Earth, around 4.6 billion years ago, with intense heat and volcanic activity. The planet was a molten rock, pummeled by space debris, and massive impacts likely shaped its formation, including the creation of the Moon. The surface was a scorching lava ocean with extreme volcanic activity, and the atmosphere consisted of toxic gases and steam. Despite these hostile conditions, Earth was setting the stage for life. As the Hadean eon came to a close around 4 billion years ago, the planet began to cool, forming a solid crust and oceans from volcanic steam and comet impacts. Ancient zircon crystals even suggest that water may have existed earlier than previously thought, slowly making the planet habitable, though devoid of life and fossils at this stage.Also read | Mice with two fathers? Scientists create fertile mice using DNA from two fathers
PHNOM PENH, July 1 (Xinhua) — A 36-year-old woman from northwest Cambodia’s Siem Reap province has been confirmed for H5N1 human avian influenza, raising the number of the cases to 11 so far this year, the Ministry of Health said in a statement on Tuesday.
“A laboratory result from the Pasteur Institute in Cambodia showed on June 30 that the woman was positive for H5N1 virus,” the statement said. “The patient has the symptoms of fever, cough, and dyspnea, and she is currently being rescued by a team of doctors.”
The victim lives in Doun Keo village of Puok district.
There were sick and dead chickens at the patient’s home. She had been in contact with those dead chickens and took them to bury.
Health authorities are looking into the source of the infection and are examining any suspected cases or people who have been in contact with the victim in order to prevent an outbreak in the community.
Tamiflu (oseltamivir), an antiviral drug to prevent the bird flu from spreading, was also given out to people who had direct contact with the patient, the statement said.
So far this year, the kingdom recorded a total of 11 human cases of H5N1 bird flu, with five deaths, according to the Ministry of Health. ■
Trump went on to suggest that the DOGE initiative, or Department of Government Efficiency, which Musk was instrumental in setting up, could be turned against the world’s richest man.
“No more Rocket launches, Satellites, or Electric Car Production, and our Country would save a FORTUNE. Perhaps we should have DOGE take a good, hard, look at this?” the president wrote.
According to an estimate by the Washington Post, Musk and his businesses have received at least $38 billion in government contracts, loans, subsidies and tax credits over the years.
Trump and Musk started the year with effusive mutual praise and months of shared photo opportunities, before the relationship apparently soured last month over differences in opinion over government debt. The two now regularly goad each other online.
In response, Musk wrote on his own social media platform, X: “I am literally saying CUT IT ALL. Now.”
The latest social media fight follows Musk’s renewed criticism of Trump’s signature “big, beautiful bill,” which is currently struggling to gain enough Republican support to pass the Senate.
Musk says the bill will balloon the U.S. national debt. On Monday, he threatened to unseat lawmakers who campaigned on reducing the deficit but will vote for it. He has also floated the idea of starting a new party if the bill passes.
The nonpartisan Congressional Budget Office estimates that the bill would increase federal deficits by about $2.4 trillion over the next decade.
Pakistan Test head coach Azhar Mahmood pictured during a training session. — PCB/File
Intriguing details have come to the fore after former Pakistan cricketer Basit Ali shed light on what led to Azhar Mahmood’s appointment as the national side’s Test head coach.
The PCB officially confirmed Mahmood’s appointment on Monday, stating that the 50-year-old will serve as acting red-ball head coach until the conclusion of his current contract in April 2026.
The former all-rounder, who signed a two-year deal with the PCB in April 2024, has previously served as the national side’s assistant coach.
Under his leadership, Pakistan will begin their ICC World Test Championship (WTC) 2025–27 campaign with a two-match home series against South Africa in October-November, followed by a two-match away series against Bangladesh in March-April 2026.
Appearing on a local YouTube channel, Ali disclosed that Misbah-ul-Haq was initially set to become the head coach, according to Geo Super.
However, a shift in preferences within the PCB hierarchy, particularly votes of support from Director of High Performance Aqib Javed and T20I captain Salman Ali Agha, led to Mahmood’s appointment instead.
“Misbah was about to become the head coach, but things change with the wind. Now, considering what Javed said and what captain Salman Ali Agha said, [Azhar] Mahmood has been made the red-ball coach — I’m telling you this with authenticity, otherwise Misbah had already been finalised as coach,” Basit stated.
“It’s because of [Salman Ali] Agha’s vote that Mahmood was given the role of interim coach. Some things are like that — we can’t speak about them openly; we also have to be considerate,” he added.
The 54-year-old also criticised the inconsistent approach taken by the PCB in coaching appointments, questioning the prolonged delay in the official announcement and the unequal treatment of mentors who were previously let go.
“This delay that’s been happening — as you just mentioned, Mahmood’s contract is until April 2026 — well, the mentors also had a three-year contract. So what happened? Why were they sidelined after being paid off?” he questioned.
He emphasised the need for consistency and fairness in decision-making, highlighting that if early terminations were acceptable in one case, they should be equally applied across the board.
“If you’re using a scale of fairness, it should be applied equally to everyone. You didn’t let the mentors work for three years. If you intended to remove them, you could have done the same here — paid one or two months’ salary and let them go,” he concluded.
Anyone who longs for the styling and analog goodness of Italian sports cars from the 1960s – but not their sketchy reliability and general unwieldiness – will be interested to learn about Mignatta and its Rina Speedster. Mignatta, a startup based in the Piedmont region of Italy, first provided photos of the Rina in May, and now the company has announced the public debut of the car.
Available Models
Ferrari
Founded
1939 (as Auto Avio Costruzioni)
Founder
Enzo Ferrari
Headquarters
Maranello, Italy
The Rina combines the gorgeous styling of something like a Ferrari 250 Testa Rossa in a modern package that includes carbon-fiber construction and an all-aluminum V8. Anyone who wants to see it in person will have their first chance at the Goodwood Festival of Speed, which runs July 10-13 in the UK The car won’t just be on static display, either. Mignatta confirmed it will make exhibition runs.
Big-Cube V8 In A Lightweight Package
Thanks to carbon-fiber construction (plus some Kevlar) for both the central tub and the body, the Rina’s dry weight is claimed by the company to be just over 2,200 pounds. The carbon tub was developed with help from Mignatta’s parent company, JM, which specializes in building carbon-fiber parts for marine applications. According to the company, it helps deliver torsional rigidity in the Rina superior to that of supercars like the Lamborghini Aventador.
Completing the chassis are tubular subframes front and rear, and suspension with overlapping arms and adjustable dampers. Mounted at each corner is a forged wheel, with the front pair measuring 19 inches in diameter and the rear measuring 20 inches. Housed within are six-piston brake calipers at the front and four-piston units at the rear, clamping down on steel rotors as standard or carbon-ceramic rotors as an option.
Mignatta
This light, ultra-stiff chassis is then combined with a 5.0-liter V8 – an all-aluminum design with double overhead cams. A power output hasn’t been mentioned yet. Mignatta also hasn’t confirmed whether the engine is Ford’s popular Coyote V8 from cars like the Mustang, though the company said the engine has been worked over by Italtecnica Engineering.
The engine sits in a front-midship position and drives the rear wheels via a six-speed manual transmission and limited-slip differential. The transmission, which includes a gated shifter, is mounted at the rear for improved weight distribution. Mignatta claims the balance is an ideal 50:50 front and rear.
No Two Examples Will Be the Same
Only 30 examples are destined for production, and if any build slots are left, Mignatta will likely be happy to accept deposits following the Goodwood debut. The company has previously announced a price tag of $290,000. This price tag will likely inflate quickly once some options are selected.
Because of the hand-built nature of the cars, Mignatta is promising a lot of customizability. The leather looks like it’s the same used in Italian shoes, while all the controls – including the gauge cluster, with real gauges, mind you – have a 1990s-like exotic look to them, as though they were leftovers from an early Pagani Zonda or something.
Related
Pagani Will Never Tire Of Making New* Zondas
This is a renewed version of the 26-year-old nameplate, a one-off made by Pagani Unico.
There’s no infotainment system dominating the center stack, either. Curiously, the company has chosen to mount the speedometer there. Underneath are some physical controls which, like the gauges, are all machined from aluminum.
Mignatta isn’t the first company to attempt a sports car combining 1960s-era styling with modern mechanicals. A few years back, a startup by the name of Jannarelly showed a speedster with styling similar to the Rina. Jannarelly wasn’t successful, but some other companies have been. One of them is historic British firm AC Cars, which recently launched a modern take on the AC Cobra.
Natilus’s BWB design offers 40% more interior capacity, which the HORIZON utilizes to make air travel more comfortable and enjoyable. Intended to have a largely customizable layout to meet the needs of each individual airline and its customer base, the HORIZON is reimagining what air travel can be with the introduction of innovative spaces for business travelers to families.
Work from the Sky in HORIZON’s Video Conference Pods
For the first time on commercial aircraft, the HORIZON will be equipped with three video conference pods that act as conference rooms for the business-oriented passengers. The pods will be compatible with both video and phone calls and will be Wi-Fi-enabled, so that passengers can continue to collaborate and be productive during flight.
Families Take Center Stage with Club Seating
The HORIZON will also include Deluxe Club Seating, where a family of four can comfortably sit two-by-two facing each other, making it easy to communicate, play, and share experiences throughout the flight. No longer limited by the dreaded middle seat, the club seating is attractive for airlines looking to cater to family units with small children.
Intelligent Lighting Connected to Infotainment
The HORIZON will be equipped with an intelligent lighting system with simulated skylights and windows that can be customized to a seating zone, mimicking natural light or ambient lighting to ease the impact of jetlag. The lighting can also be coordinated with the infotainment screens to create an immersive entertainment experience.
HORIZON: Benefits of 40% More Capacity
With its unique blended-wing body design, the dramatic gains in interior cabin space translate to an entirely new experience for passengers. In this new design, the HORIZON boasts:
Luxe, lie-flat first class seats that allow travelers to rest during long-haul flights, evoking a sense of a private retreat;
Economy seats where every passenger enjoys their own dedicated seat with back-of-seat infotainment systems, featuring a wide selection of movies, music, and connectivity options to make the journey as enjoyable as it is efficient;
Tall ceiling heights at 7.5 feet to make the cabin feel even more spacious; and
Eight exit doors for ease of egress, with the possibility for carriers to opt for double doors.
“The HORIZON is an innovative aircraft that ushers in a new era of air travel, offering significantly more interior space—which we’ve used to create a more comfortable and enjoyable cabin,” said Aleksey Matyushev, CEO and Co-founder of Natilus. “This aircraft will provide our commercial airline customers with the ultimate platform to elevate the passenger experience.”
About Natilus Natilus is a San Diego-based developer of hyper-efficient blended-wing-body (BWB) aircraft designed to transport people and cargo more sustainably and efficiently than ever before. Natilus’s BWB aircraft unlocks improved aviation economics by reducing fuel consumption by 30% while increasing payload capability by 40%.The Natilus team is comprised of innovators from General Atomics, Northrop Grumman, Skunkworks, SpaceX, and Piper Aircraft. Learn more at natilus.co.
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
“We are pleased to continue our ongoing partnership with Apellis and share their strong belief in Aspaveli/EMPAVELI’s potential to deliver significant long-term growth,” said Guido Oelkers, Chief Executive Officer at Sobi. “We look forward to continuing the regulatory process in Europe and are well positioned to bring this novel treatment to patients with C3G and IC-MPGN leveraging our deep rare disease expertise.”
Aspaveli/EMPAVELI is approved in the European Union, other countries globally, and the US for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia, a rare blood disorder. It is currently under review in the European Union and the U.S. for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare kidney diseases. An opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) is expected before year-end. In the U.S., the Prescription Drug User Fee Act (PDUFA) action date is July 28, 2025.
“Through our collaboration, Sobi has developed a deep understanding of Aspaveli/EMPAVELI’s potential to significantly improve patient outcomes and deliver long-term value as a rare disease franchise,” said Timothy Sullivan, Chief Financial Officer, Apellis. “This transaction reflects our shared conviction in the potential of Aspaveli/EMPAVELI to transform the treatment landscape for patients with rare diseases, including C3G and IC-MPGN.”
Transaction Highlights
Upfront Payment: $275 million in cash.
Milestone Payments: Up to $25 million upon EMA approval of Aspaveli® for C3G and IC-MPGN.
Royalty Structure: Sobi will reduce its ex-U.S. royalty obligation to Apellis Pharmaceuticals, Inc. by 90% until defined caps are achieved, after which ex-U.S. royalties revert to the original license agreement.
About the Sobi and Apellis Collaboration Sobi and Apellis have global co-development rights for systemic pegcetacoplan.
Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.
About C3 Glomerulopathy (C3G) and Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis.1 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence.2 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.3
About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 1 July 2025 at 1:00 PM CEST.
Gerard Tobin
Head of Investor Relations
References
1. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. https://ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed November 21, 2019.
2. Tarragón, B, et al. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology. August 2024; 19(8)1005-1015. doi: 10.2215/CJN.0000000000000474.
